Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: A10AB06

Apidra(insulin glulisine)

Diabetes Mellitus

Marketing Authorisation Holder: sanofi-aventis Deutschland GmbH

EMA Authorisation: 27/09/2004

INN: insulin glulisine

Indication

Treatment of adults, adolescents and children, six years or older with diabetes mellitus, where treatment with insulin is required.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Apidra — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.